Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout
Biotech buyouts are all the rage these days. Today, it’s Alexion’s $ALXN turn to score with a deal that adds a Phase III drug for a rare disease to its pipeline — marking the new executive crew’s “first step” in reorganizing the pipeline.
Alexion struck a deal to buy Stockholm-based Wilson Therapeutics for $855 million in cash, offering its backers a rich payday after gathering a set of mid-stage data demonstrating their drug can flush excess copper from the blood of patients with Wilson disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
